Related Experiment Video
Updated: Aug 7, 2026

11:10
Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
Published on: December 28, 2010
Therapeutic HIV vaccine trial launched in Canada
Canadian HIV/AIDS Policy & Law Review
|November 16, 2004
Abstract:
The first-ever clinical trial of a therapeutic HIV vaccine in Canada is currently underway. The trial is being run by the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) in cooperation with Aventis Pasteur, of France, and the Immune Response Corporation (IRC), of the United States.
Insights
Canada is conducting its first therapeutic HIV vaccine clinical trial. This groundbreaking study involves the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) and international partners.
Area of Science:
- Immunology
- Vaccinology
- Clinical Trials
Background:
- The first therapeutic HIV vaccine clinical trial in Canada is actively underway.
- This significant research is a collaborative effort involving the Canadian Network for Vaccines and Immunotherapeutics (CANVAC).
Discussion:
- The trial involves international cooperation with Aventis Pasteur (France) and the Immune Response Corporation (United States).
- This initiative marks a critical step in developing therapeutic interventions for HIV.
Key Insights:
- Canada pioneers therapeutic HIV vaccine research on its soil.
- Collaboration between national and international entities is key to advancing HIV vaccine development.
Outlook:
- This trial could pave the way for new HIV treatment strategies.
- Further research and development are anticipated based on trial outcomes.

